MLIP
Basic information
Region (hg38): 6:53929982-54266280
Previous symbols: [ "C6orf142" ]
Links
Phenotypes
GenCC
Source:
- myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis (Strong), mode of inheritance: AR
- myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis (Strong), mode of inheritance: AR
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis | AR | Cardiovascular; Musculoskeletal | The condition can involve cardiomyopathy and/or arrhythmia, and awareness may allow prompt diagnosis and mangement; Individuals may be at risk of rhabdomyolysis, and awareness may allow avoidance of precipitating factors, and prompt treatment of episodes | Cardiovascular; Musculoskeletal | 34581780; 34935254; 35672413; 35915960 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the MLIP gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 0 | |||||
missense | 22 | 26 | ||||
nonsense | 0 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 0 | |||||
non coding | 0 | |||||
Total | 0 | 2 | 22 | 1 | 3 |
Variants in MLIP
This is a list of pathogenic ClinVar variants found in the MLIP region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
6-54019068-A-G | Inborn genetic diseases | Likely benign (Aug 28, 2021) | ||
6-54121496-C-T | Inborn genetic diseases | Uncertain significance (Oct 04, 2024) | ||
6-54124549-C-T | Inborn genetic diseases | Uncertain significance (Jul 05, 2023) | ||
6-54124564-C-T | Inborn genetic diseases | Uncertain significance (Feb 15, 2023) | ||
6-54124577-A-C | Inborn genetic diseases | Uncertain significance (Feb 06, 2023) | ||
6-54124591-C-A | Inborn genetic diseases | Uncertain significance (Feb 06, 2023) | ||
6-54124611-C-A | Inborn genetic diseases | Uncertain significance (Dec 21, 2022) | ||
6-54124648-T-C | Inborn genetic diseases | Uncertain significance (Jul 06, 2021) | ||
6-54124699-GC-G | Likely pathogenic (Jun 13, 2023) | |||
6-54124708-G-C | Inborn genetic diseases | Uncertain significance (Mar 06, 2023) | ||
6-54124758-A-T | Inborn genetic diseases | Uncertain significance (Feb 27, 2023) | ||
6-54124780-G-A | Inborn genetic diseases | Uncertain significance (Dec 27, 2023) | ||
6-54124840-T-C | Inborn genetic diseases | Uncertain significance (May 11, 2022) | ||
6-54124848-C-T | Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis | Pathogenic (Oct 18, 2024) | ||
6-54124860-G-T | Inborn genetic diseases | Uncertain significance (Dec 16, 2023) | ||
6-54124861-G-A | Inborn genetic diseases | Uncertain significance (Apr 17, 2023) | ||
6-54137630-A-G | Uncertain significance (Jun 08, 2023) | |||
6-54137807-CA-C | Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis | Pathogenic (Oct 18, 2024) | ||
6-54137812-G-A | Likely benign (Oct 01, 2024) | |||
6-54137894-A-T | Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis | Pathogenic (Oct 18, 2024) | ||
6-54137898-GT-G | Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis | Pathogenic (Oct 18, 2024) | ||
6-54149059-T-A | Inborn genetic diseases | Uncertain significance (May 23, 2023) | ||
6-54149075-G-A | Inborn genetic diseases | Conflicting classifications of pathogenicity (Nov 13, 2024) | ||
6-54149109-AT-A | Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis | Pathogenic (Oct 18, 2024) | ||
6-54149122-C-T | Myopathy with myalgia, increased serum creatine kinase, and with or without episodic rhabdomyolysis | Pathogenic (Oct 18, 2024) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
MLIP | protein_coding | protein_coding | ENST00000274897 | 13 | 336299 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
3.16e-16 | 0.00985 | 125703 | 0 | 44 | 125747 | 0.000175 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -0.710 | 266 | 235 | 1.13 | 0.0000114 | 2964 |
Missense in Polyphen | 84 | 88.341 | 0.95086 | 1145 | ||
Synonymous | -0.613 | 97 | 89.6 | 1.08 | 0.00000462 | 895 |
Loss of Function | 0.0556 | 24 | 24.3 | 0.988 | 0.00000108 | 320 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.000608 | 0.000597 |
Ashkenazi Jewish | 0.00 | 0.00 |
East Asian | 0.000109 | 0.000109 |
Finnish | 0.00 | 0.00 |
European (Non-Finnish) | 0.000161 | 0.000158 |
Middle Eastern | 0.000109 | 0.000109 |
South Asian | 0.000329 | 0.000327 |
Other | 0.00 | 0.00 |
dbNSFP
Source:
- Function
- FUNCTION: Required for precocious cardiac adaptation to stress through integrated regulation of the AKT/mTOR pathways and FOXO1. Regulates cardiac homeostasis and plays an important role in protection against cardiac hypertrophy. Acts as a transcriptional cofactor, represses transactivator activity of ISL1 and MYOCD. {ECO:0000250|UniProtKB:A0A096MK47, ECO:0000250|UniProtKB:Q5FW52}.;
Intolerance Scores
- loftool
- rvis_EVS
- 0.24
- rvis_percentile_EVS
- 69.51
Haploinsufficiency Scores
- pHI
- 0.728
- hipred
- N
- hipred_score
- 0.123
- ghis
- 0.487
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- N
- gene_indispensability_score
- 0.114
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Mlip
- Phenotype
- cardiovascular system phenotype (the observable morphological and physiological characteristics of the mammalian heart, blood vessels, or circulatory system that are manifested through development and lifespan); mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); muscle phenotype; homeostasis/metabolism phenotype;
Gene ontology
- Biological process
- negative regulation of transcription by RNA polymerase II;negative regulation of cardiac muscle hypertrophy;positive regulation of transcription by RNA polymerase II;negative regulation of cardiac muscle hypertrophy in response to stress
- Cellular component
- nucleus;nuclear envelope;PML body;nuclear lumen;sarcolemma
- Molecular function